Coronavirus Infections: Clinical Trials

722 trials for Coronavirus Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

403 completed, 149 unknown, 71 terminated, 56 withdrawn. 722 Phase 1, 268 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1722Completed 403, Unknown 149, Terminated 71, Withdrawn 56, Recruiting 19, Active not recruiting 14, Not yet recruiting 10
Phase 2268Completed 133, Unknown 66, Terminated 27, Withdrawn 25, Recruiting 10, Active not recruiting 4, Not yet recruiting 3

Follow Coronavirus Infections: new trials by email Literature Review of Coronavirus Infections trials Research Report on Coronavirus Infections

Trials (filtered) newest first · largest first

All 722 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
IV infusion using an isolated, placental, mesenchymal stem cell derived EVs, Placebo IV administration - COVID-19
Phase 1 / Phase 2Not yet recruitingKimera Labs Inc.642027-01-012026-06-24
Taurine Supplementation in Adolescents With Post-COVID Condition
Taurine - Long COVID, Post COVID-19 Condition
Phase 1 / Phase 2Not yet recruitingUniversity of Alberta302026-12-302026-10-16
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
AVM0703, Placebo - ARDS, Covid19
Phase 1Not yet recruitingAVM Biotechnology Inc162026-12-012026-11-02
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Keytruda - Post-Acute COVID-19 Syndrome
Phase 1Not yet recruitingNational Institute of Neurological Disorders and Stroke (NINDS)152026-11-252026-11-20
Pancoronavirus Vaccine Study in Healthy Adults Ages 18-55
Cov-RBD-scNP-001, ACU-026-001-1 - Coronavirus Infection
Phase 1Not yet recruitingDuke University362026-11-162026-10-29
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
RVX-sCPD9 - COVID -19
Phase 1Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)802026-10-262026-11-20
Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 Years
BMI2012 low-dose, Placebo low-dose, BMI2012 mid-dose - Prevention of COVID-19 Variant (Omicron JN.1)
Phase 1Not yet recruitingBMI Korea722026-10-012026-08-28
Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
SARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50, SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50, SARS-CoV-2 Omicron EG.5.1 challenge agent 10^4 TCID50 - SARS-CoV-2 (COVID-19)
Phase 1RecruitingImperial College London382026-07-102026-07-17
Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster
Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg - Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)
Phase 1Not yet recruitingThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)902026-07-012026-06-10
Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS
Human umbilical cord mesenchymal stem cells + best supportive care, Placebo control + best supportive care - COVID-19, ARDS
Phase 1 / Phase 2WithdrawnBaylx Inc.2026-06-012025-12-29
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
OCU500 - COVID-19
Phase 1Active not recruitingNational Institute of Allergy and Infectious Diseases (NIAID)832026-05-262026-11-20
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet - Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19)
Phase 1CompletedPfizer172026-04-132026-07-28
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
MDX2301, Normal Saline - COVID -19, COVID-19 (Prevention)
Phase 1RecruitingModeX Therapeutics, An OPKO Health Company802026-03-242026-09-10
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Kisspeptin 112-121 - Reproductive Disorder, Neurodegeneration
Phase 1RecruitingStephanie B. Seminara, MD402026-03-102026-07-13
A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine - Influenza, Human+COVID-19
Phase 1RecruitingGlaxoSmithKline2252026-03-092026-06-30
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
COVID-19 Vaccines - COVID - 19, SARS CoV-2
Phase 1Active not recruitingRokote Laboratories Finland Oy202026-02-102026-07-22
Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
PepGNP-COVID19, Sterile Water for Injection - COVID-19
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)602026-02-022026-10-30
A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults
GC4006A, Normal Saline - COVID - 19
Phase 1Active not recruitingGC Biopharma Corp722026-01-282026-11-16
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
Aluminum Hydroxide Suspension, Boost-2867, CpG 7909 - COVID-19
Phase 1Active not recruitingNational Institute of Allergy and Infectious Diseases (NIAID)1402025-12-052026-11-20
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032), Placebo - COVID-19, SARS-CoV-2 Infection
Phase 1 / Phase 2RecruitingKara Chew802025-10-212026-08-18

Showing 20 of 722. Sign in to see all of them.

Narrower conditions

COVID-19 (675)  ·  Respiratory Distress Syndrome (34)  ·  Severe Acute Respiratory Syndrome (33)  ·  Pneumonia (25)  ·  Virus Diseases (23)  ·  Post-Acute COVID-19 Syndrome (14)  ·  Pneumonia, Viral (12)  ·  Acute Lung Injury (10)  ·  Influenza, Human (10)  ·  Infections (9)  ·  Communicable Diseases (8)  ·  Cytokine Release Syndrome (7)  ·  Lung Diseases (7)  ·  Respiratory Tract Infections (7)

Broader conditions

Coronaviridae Infections (721)  ·  Nidovirales Infections (721)  ·  RNA Virus Infections (718)  ·  Infections (713)  ·  Virus Diseases (699)  ·  Respiratory Tract Diseases (691)  ·  Respiratory Tract Infections (685)  ·  Lung Diseases (680)  ·  Pneumonia, Viral (673)  ·  Pneumonia (661)  ·  Pathological Conditions, Signs and Symptoms (66)  ·  Pathologic Processes (56)  ·  Respiration Disorders (46)  ·  Disease Attributes (29)

Interventions

Saline Solution (26)  ·  Sodium Chloride (26)  ·  Standard of Care (19)  ·  Ritonavir (12)  ·  nirmatrelvir and ritonavir drug combination (12)  ·  COVID-19 Vaccines (10)  ·  BNT162 Vaccine (9)  ·  Injections (9)  ·  nirmatrelvir (9)  ·  Ivermectin (8)  ·  2019-nCoV Vaccine mRNA-1273 (7)  ·  ChAdOx1 nCoV-19 (7)  ·  COVID-19 Serotherapy (6)  ·  CVnCoV COVID-19 vaccine (6)  ·  Hydroxychloroquine (6)

Sponsors

Pfizer (25)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (18)  ·  AstraZeneca (9)  ·  ImmunityBio, Inc. (8)  ·  BioNTech SE (7)  ·  Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (7)  ·  Regeneron Pharmaceuticals (7)  ·  Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (6)  ·  University of Oxford (6)  ·  GeneOne Life Science, Inc. (5)  ·  GlaxoSmithKline (5)  ·  Sinocelltech Ltd. (5)  ·  Sorrento Therapeutics, Inc. (5)  ·  Stanford University (5)  ·  CanSino Biologics Inc. (4)

Countries

United States (233)  ·  China (81)  ·  Australia (32)  ·  United Kingdom (28)  ·  Brazil (27)  ·  Russia (20)  ·  South Korea (20)  ·  Belgium (19)  ·  Canada (17)  ·  Germany (17)  ·  Mexico (16)  ·  South Africa (16)  ·  Israel (13)  ·  Spain (12)  ·  Indonesia (11)

Top investigators

Mike Royal, MD (4)  ·  Fengcai Zhu, Doctor (3)  ·  William Cameron, MD (3)  ·  Yao Zhang (3)  ·  Anya Loncaric (2)

Results publications

PMID 34473343, PMID 35713300, PMID 36435633, PMID 37231296, PMID 31986264, PMID 36147329, PMID 32125452, PMID 32257537, PMID 32896291, PMID 33306989, PMID 33617777, PMID 33873199, PMID 34551869, PMID 34658014, PMID 34890537, PMID 35316221, PMID 35547849, PMID 35660738, PMID 37354048, PMID 37699630, PMID 38181791, PMID 39636474, PMID 39749328, PMID 40632654, PMID 10051178, PMID 10415784, PMID 10669330, PMID 11023960, PMID 110688, PMID 11440640, PMID 11886437, PMID 12563677, PMID 1406879, PMID 14719037, PMID 15663512, PMID 16011702, PMID 16051812, PMID 16625202, PMID 16787239, PMID 17181919, PMID 18073382, PMID 18097874, PMID 18369153, PMID 18552864, PMID 18778201, PMID 19355966, PMID 19397687, PMID 19420084, PMID 19453649, PMID 19564349

NIH funding

2023 (6), 5UM1AI148373-05 (2), 5UM1AI148684-02 (2), 2025 (1), 272201300017C-18-0-1 (1), P30CA033572 (1), P30CA047904 (1), P30CA138292 (1), R01HL109448 (1), R37HD043341 (1), R44HL158446 (1), U01AI172800 (1)